Research programme: long-acting gamma interferon - Bolder BioTechnology

Drug Profile

Research programme: long-acting gamma interferon - Bolder BioTechnology

Alternative Names: BBT-046; Gamma Interferon Long Acting; TNF-γ long acting

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bolder BioTechnology
  • Class Antifungals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mycoses

Most Recent Events

  • 04 Dec 2017 Long-acting gamma interferon is still in preclinical development for mycoses in USA (Bolder Biotechnology pipeline, December 2017)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Immunodeficiency-disorders in USA (Parenteral)
  • 31 Aug 2010 Preclinical development in Immunodeficiency disorders is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top